Lakefront Biotherapeutics NV appointed Eric Hedrick, MD, as Chief Medical Officer to strengthen its leadership team and advance its R&D pipeline following the acquisition of Ouro Medicines' operational assets. Hedrick, who previously served as clinical evaluation lead for new pipeline opportunities, will report to Henry Gosebruch, CEO, and join the company's Management Committee. The appointment, announced on June 8, 2026, aligns with Lakefront's strategic transformation and focus on oncology and immunology & inflammation programs.

Hedrick brings over 25 years of experience in developing therapies in the pharmaceutical and biotechnology industry. Prior to joining Lakefront in July 2025, he held leadership roles at EQRx, BeiGene, Epizyme, and Pharmacyclics. He began his career at Genentech and received his M.D. from the University of Maryland. His expertise is expected to drive the clinical development of gamgertamib and other future programs.

Strategic Context

The appointment follows Lakefront's acquisition of Ouro Medicines' operational assets on June 4, 2026. The Ouro portfolio is now a cornerstone of Lakefront's R&D pipeline, focusing on areas with unmet medical needs. Hedrick's role will be pivotal in advancing these programs and leveraging his experience in drug development.

Leadership Background

Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company focused on identifying, acquiring, and advancing promising opportunities in oncology and immunology & inflammation. The company employs a modality-agnostic approach to asset selection and prioritizes programs with clear clinical proof-of-concept.